They rate a 1 of 1 out of 100 rating which is practically unheard of for the broker and is updated each week on Friday. Not sure what the bullishness is with the broker considering all of the other downgrades. I will call them and see what they say.
THE NONSENSE FROM THEM
Today's Dead Cat Bounce Stock: ZIOPHARM Oncology (ZIOP)
Trade-Ideas LLC identified ZIOPHARM Oncology ( ZIOP) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified ZIOPHARM Oncology as such a stock due to the following factors:
ZIOP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $22.4 million.
ZIOP has traded 778,282 shares today.
ZIOP is up 3.1% today.
ZIOP was down 8.2% yesterday.
Over time analysts' credibility has been compromised by the increased frequency of the grading. In the prior market, Upgrades and Downgrades would be a once a year, once every two years or an event based upon changes in sentiment and conditions. Long term investing has given way to logarithmic computer model day trading and therefore the volatility and stock movement has been compressed. Historically projections have been for a One Year Price Target, but considering the current circumstance I feel that the Price Target should reflect a current valuation and not a future estimation.
Easiest Short in history as Bankruptcy is eminent.
Pernix Theraputics should sell Zohydro to Purdue Pharma and get the monkey of its back.
March 15, 2016, 8:10 AM EDT
Full article is at Google and search by headline
Battery-hungry world turns its attention to South America.
Far from the soy and cattle that dominate its vast fertile pampas, Argentina harbors another valuable commodity that is rocketing in price and demand and luring newly welcomed foreign investors.
Lithium, the so-called “white petroleum,” drives much of the modern world. It forms a small but essentially irreplaceable component of rechargeable batteries, used in consumer devices like mobile phones and electric cars. It also has pharmaceutical and other applications.
Over half of the earth’s identified resources of the mineral are found in South America’s “lithium triangle,” an otherworldly landscape of high-altitude lakes and bright white salt flats that straddles Chile, Argentina, and Bolivia.
But that may be all about to change.
In Chile, a sale of state lithium deposits and a shake-up in the way the country manages its resources has awakened interest from everyone from early stage mining companies to electric carmakers like Tesla
“For 10 or 12 years, (Argentina) was a do-not-invest zone. The tone of doing business has just swung 180 degrees,” said Tom Hodgson, the chief executive of Western Lithium, which is developing a project in the country due to begin production next year.
Argentina now has a “major opportunity” to build a lithium export business, Hodgson told Reuters earlier this month at a mining conference in Toronto.
Western Lithium is working with Korean steelmaker POSCO , whose chairman was in Argentina last month to meet with Macri and begin the construction of a new lithium plant, due to begin commercial production within a year. The exploratory mining company Orocobre is also developing a project.
Zogenix Beats Q4 Estimates
4:04 PM ET, 03/10/2016 - MT Newswires
04:04 PM EST, 03/10/2016 (MT Newswires) -- Zogenix (ZGNX) says Q4 sales fell to $6.1 million from $9.9 million in the year-ago period but topped the CapIQ mean for $5.52 million.
Net loss narrowed to $0.36 per share from a loss of $1.09 last year and was better than the GAAP estimate for a $0.73 loss and a normalized loss of $0.74.
The Vista Voice
March 11, 2016
Pernix Therapeutics Holdings Inc (NYSE:PTX) had its target price lowered by stock analysts at Brean Capital from $8.00 to $5.00 in a report issued on Friday, ARN reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Brean Capital’s price target would suggest a potential upside of 171.74% from the stock’s previous close.
Short sighted lowly compensated writers seem to be amusing themselves today by bashing a struggling biotechnology company which is inventing drugs that could benefit humankind and possibly save their lives.
1. Initiated a Phase 2 proof-of-concept study of XOMA 358 in patients with congenital hyperinsulinism, a rare genetic disorder in which the insulin cells of the pancreas secrete inappropriate and excessive insulin.
2. Licensed its first-in-class TGF-beta immuno-oncology antibody program to Novartis for an upfront payment of $37 million, potential milestone payments of up to $480 million and tiered royalties up to low double digits.
3. Extended the maturity date of its $13.5 million note due to Novartis until September 2020.
4. Licensed XMetA, its selective insulin receptor modulator antibody program for diabetes, to Novo Nordisk A/S for an upfront payment of $5 million, potential milestone payments of up to $290 million and tiered royalties.
5. Sold biologics manufacturing facility to Agenus Inc.
6. Divested anti-botulinum toxin program to Nanotherapeutics, Inc.
7. Closed the remaining gevokizumab clinical programs; initiating licensing efforts.
8. Reduced headcount by half to approximately 90.
9. Achieved cash runway to finance endocrine franchise into 2017.
GTx Narrows Q4 Loss Vs Yr Ago, Beats EPS Estimates
11:06 AM ET, 03/03/2016 - MT Newswires
11:06 AM EST, 03/03/2016 (MT Newswires) -- GTx (GTXI) reported a Q4 net loss of $3.2 million, or $0.04 per share, increasing from a loss of $0.13 per share for the same quarter last year, and beating the Capital IQ consensus estimate for a loss of $0.10 per share.